Article
Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma.
Molecular diagnosis & therapy - 1 Jun 2015
Li Yonghong, Bare Lance A, Bender Richard A, Sninsky John J, Wilson Leslie S, Devlin James J, Waldman Frederic M
Abstract excerpt
OBJECTIVE: To determine whether a next-generation sequencing (NGS) panel of 34 cancer-associated genes would cost-effectively aid in the treatment selection for patients with metastatic melanoma, compared with a single-site BRAF V600 mutation test. METHODS: A decision model was developed to estimate the costs and health outcomes of the two test strategies. The cost effectiveness of these two strategies was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.